Ficerafusp alfa + Pembrolizumab (KEYTRUDA®) + Placebo
Phase 2/3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Trial Timeline
Jan 28, 2025 → Jul 1, 2029
NCT ID
NCT06788990About Ficerafusp alfa + Pembrolizumab (KEYTRUDA®) + Placebo
Ficerafusp alfa + Pembrolizumab (KEYTRUDA®) + Placebo is a phase 2/3 stage product being developed by Bicara Therapeutics for Metastatic Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06788990. Target conditions include Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Head and Neck Squamous Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
15
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06788990 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Metastatic Head and Neck Squamous Cell Carcinoma